Who
Diana Hausman
Director
Company insider
Files Form 4 as: Director, Immuneering; Chief Medical Officer, Zentalis Pharmaceuticals; Chief Medical Officer, Zymeworks; Chief Medical Officer, Oncothyreon.
In numbers
- Trades disclosed
- 55
- Buys
- 2
- Sells
- 6
- Bought
- $47K
- Sold
- $3.3M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 12 Dec 2012
- Last trade
- 11 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 11 Jun 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 11 Jun 2026filed 11 Jun 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 2 Jul 2025filed 7 Jul 2025 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $9,0002,500 at $3.60 | filing |
| 2 Jul 2025filed 7 Jul 2025 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $11K3,000 at $3.62 | filing |
| 13 Jun 2025filed 16 Jun 2025 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 9 May 2024filed 9 May 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $42K3,356 at $12.62 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —337,500 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —337,500 at $0.00 | filing |
| 14 Jun 2023filed 15 Jun 2023 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 8 May 2023filed 10 May 2023 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —39,732 at $0.00 | filing |
| 21 Jun 2022filed 23 Jun 2022 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,185 at $0.00 | filing |
| 14 Jan 2022filed 18 Jan 2022 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | $328K25,200 at $13.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | Zymeworks | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | Zymeworks | SEC FORM 4 Sold | $37K1,048 at $34.95 | filing |
| 10 Mar 2021filed 12 Mar 2021 | Zymeworksoption or derivative | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | Zymeworksoption or derivative | SEC FORM 4 Code A | —48,750 at $0.00 | filing |
| 10 Mar 2021filed 12 Mar 2021 | Zymeworksoption or derivative | SEC FORM 4 Code A | —8,125 at $0.00 | filing |
| 7 Jan 2021filed 11 Jan 2021 | Zymeworks | SEC FORM 4 Code A | $6,400207 at $30.92 | filing |
| 4 Dec 2020filed 4 Dec 2020 | Zymeworksoption or derivative | SEC FORM 4 Code M | —2,850 at $0.00 | filing |
News
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractZNTL · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Diana Hausman; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.